{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:10:00Z","timestamp":1788786600953,"version":"build-2803163510"},"reference-count":12,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Relapse remains a major challenge in the long-term management of pulmonary sarcoidosis, yet predictors of relapse-free survival in patients with early-stage disease are incompletely understood. We investigated the clinical determinants of time to relapse in a biopsy-confirmed cohort of patients with pulmonary sarcoidosis followed for up to 15 years. Methods: This retrospective cohort study included 200 adults (mean age 42.0 \u00b1 11.2 years, 72.0% women) with biopsy-confirmed Stage I\u2013II pulmonary sarcoidosis. The primary outcome was relapse requiring re-initiation or escalation of systemic therapy after remission. Relapse-free survival was evaluated using Kaplan\u2013Meier analysis and compared by the log-rank test. Cox proportional hazards models were used to identify independent predictors of relapse. Results: During long-term follow-up, 36 patients (18.0%) experienced disease relapse. Relapse-free survival was significantly lower among patients who received systemic treatment at baseline than among untreated patients (log-rank p &lt; 0.001). In multivariable Cox analysis, baseline systemic treatment (adjusted hazard ratio [HR] 4.27, 95% confidence interval [CI] 1.39\u201313.09; p = 0.011) and Scadding Stage II disease (HR 2.58, 95% CI 1.26\u20135.29; p = 0.010) independently predicted relapse. Increasing age was associated with a lower relapse risk (HR 0.70 per 10-year increase, 95% CI 0.50\u20131.00; p = 0.047). Baseline FVC and sex were not independently associated with relapse, while extrapulmonary involvement showed a borderline association (HR 2.16, 95% CI 0.97\u20134.80; p = 0.059). Conclusions: Long-term relapse-free survival in early pulmonary sarcoidosis is primarily determined by baseline disease phenotype. Stage II disease identifies patients at increased relapse risk, whereas the association between systemic treatment and relapse most likely reflects confounding by indication rather than a detrimental treatment effect. Time-to-event analysis provides a clinically relevant framework for long-term risk stratification in early-stage sarcoidosis.<\/jats:p>","DOI":"10.3390\/jcm15176875","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:12:25Z","timestamp":1788783145000},"page":"6875","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Predictors of Relapse-Free Survival in Early Pulmonary Sarcoidosis"],"prefix":"10.3390","volume":"15","author":[{"given":"Fatma I\u015f\u0131l","family":"Uzel","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Koc University School of Medicine, 34010 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6231-9450","authenticated-orcid":false,"given":"Burak","family":"Uzel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medicana Atak\u00f6y Hospital, 34158 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Esin","family":"Yent\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Yedikule Chest Diseases and Surgery Hospital, 34020 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-6538","authenticated-orcid":false,"given":"Y\u00fcksel","family":"Peker","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Koc University School of Medicine, 34010 Istanbul, T\u00fcrkiye"},{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden"},{"name":"Department of Clinical Sciences, Respiratory Medicine and Allergology, Faculty of Medicine, Lund University, 22185 Lund, Sweden"},{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and treatment of pulmonary sarcoidosis: A review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.2.5261.1165","article-title":"Prognosis of intrathoracic sarcoidosis in England: A review of 136 cases after five years\u2019 observation","volume":"2","author":"Scadding","year":"1961","journal-title":"Br. Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2213-2600(25)00338-8","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: A World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","volume":"14","author":"Wells","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_6","first-page":"e2021026","article-title":"Incidence and baseline characteristics of relapse or exacerbation in patients with pulmonary sarcoidosis in Japan","volume":"38","author":"Murata","year":"2021","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108894","DOI":"10.1016\/j.rmed.2026.108894","article-title":"Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis","volume":"258","author":"Hashim","year":"2026","journal-title":"Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106819","DOI":"10.1016\/j.rmed.2022.106819","article-title":"The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP)","volume":"196","author":"Judson","year":"2022","journal-title":"Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00408-015-9826-3","article-title":"Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: A population-based study","volume":"194","author":"Ungprasert","year":"2016","journal-title":"Lung"},{"key":"ref_10","first-page":"248","article-title":"Clinical presentations and diagnostic work-up in sarcoidosis: A series of Turkish cases","volume":"59","author":"Kiter","year":"2011","journal-title":"Tuberc. Thorac."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1440-1843.2010.01878.x","article-title":"Extrapulmonary involvement in patients with sarcoidosis in Turkey","volume":"16","author":"Okumus","year":"2011","journal-title":"Respirology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e003495","DOI":"10.1136\/bmjresp-2025-003495","article-title":"Sarcoidosis relapse risk factors: A single-centre retrospective cluster analysis","volume":"13","author":"Bertuccio","year":"2026","journal-title":"BMJ Open Respir. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6875\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:36:34Z","timestamp":1788784594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":12,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176875"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176875","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]}}}